US: Unaffordable Insulin Endangers Lives, Says HRW [Eurasia Review] - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
April 13, 2022 Newswires
Share
Share
Post
Email

US: Unaffordable Insulin Endangers Lives, Says HRW [Eurasia Review]

Eurasia Review

The US government's failure to ensure equal and affordable access to insulin violates the right to health for people with diabetes and regularly leads to tragic consequences for many of them, Human Rights Watch said in a report released today.

The 92-page report, "'If I'm Out of Insulin, I'm Going to Die:' United States' Lack of Regulation Fuels Crisis of Unaffordable Insulin," describes the human rights impacts of US government policies that make essential life-saving medication like insulin unaffordable for many people. Human Rights Watch found that exorbitant insulin prices and inadequate health insurance coverage can cause people to pay high out-of-pocket costs for insulin, contributing to dangerous and potentially lethal medicine rationing, forcing people to forgo other basic needs, and disproportionately affecting socially and economically marginalized groups.

"People who need insulin shouldn't have to break the bank just to survive, but in the US they often do," said Matt McConnell, economic justice and rights researcher at Human Rights Watch. "Since the US doesn't regulate drug prices or ensure adequate coverage for insulin costs, countless people who can't afford expensive insulin are not only straining their financial resources but paying with their health, lives, and livelihoods."

About 27 million adults in the United States have been diagnosed with diabetes, and about 8 million adults use one or more types of insulin to regulate their blood sugar. Without it, people may experience high blood sugar, or hyperglycemia, which can lead to serious and even life-threatening complications. But in the US, the most commonly prescribed form of this life-saving drug- insulin analogs - can cost more than US$300 for a single vial, easily adding up to more than $1,000 a month if they do not have adequate health insurance coverage.

The drivers behind these high prices are clear. Unlike most other countries, the US does not directly regulate drug prices. There are no systems to establish a fair price for medicines before they enter the market or restrict how much manufacturers or intermediaries can increase prices. Analog insulin prices in the US are more than eight times the average across 32 other countries in the Organization for Economic Co-operation and Development.

"We are the wealthiest country in the world, but people have to go without medication," said Emily Grant, 29, of Dallas, Texas, discussing the cost of her insulin. "There's nothing I can do about the trajectory of my illness except follow the treatment plans my doctors tell me. And I don't think it's okay to say, 'Oh well, you either afford it or you die.'"

Human Rights Watch interviewed 50 people, including 31 with chronic health conditions, 18 of whom had insulin-dependent diabetes. Human Rights Watch also reviewed extensive secondary sources and publicly available price data for three of the most widely used insulin analogs: Humalog, Novolog, and Lantus. Each of these drugs is produced by one of the three multinational pharmaceutical manufacturers that collectively dominate the global market for insulin, respectively: the US-based Eli Lilly; the Danish company Novo Nordisk; and the French company Sanofi.

These manufacturers have increased the prices for these drugs by hundreds of percentage points, when adjusted for inflation, since their introduction to the market in the late 1990s and early 2000s, according to information these companies submitted to government inquiries and other publicly available data Human Rights Watch reviewed. Although these rapid price increases have slowed or ceased in recent years under scrutiny by policymakers, patients, advocates, and the media, prices are still high and adversely affect the lives of people who do not have adequate health insurance or charitable aid to help mitigate costs.

Almost every insulin-dependent person interviewed said they had rationed analog insulin because it was so expensive, taking less medicine than recommended by their doctor to stretch out their supply. Human Rights Watch also found that high out-of-pocket costs can undermine the standard of living for people who require insulin, as a larger percentage of their income goes toward this life-saving medicine instead of other basic needs, like food, rent, and housing.

The burdens from high drug costs are inherently regressive, as poorer people must pay a much higher share of their income for their medicine, all other factors being equal. Communities that have been historically marginalized, discriminated against, and underserved in the US are also disproportionately affected both by diabetes and its negative health outcomes. For example, although about 356 people with diabetes underwent a lower-limb amputation every day in the US in 2016, Black adults were more than twice as likely to experience a diabetes-related amputation as white adults.

Unaffordable insulin undermines human rights under international law, including the right to the highest attainable standard of health, the right to equal and affordable access to essential medicines, the right to equal protection under the law and non-discrimination, and the right to an adequate standard of living.

The US government should enact policies to ensure that essential medications like insulin are affordable to everyone who needs it, regardless of insurance, wealth, or citizenship status. This may require legislation to lower and regulate the prices for essential medications like insulin. Congress should also improve the affordability and availability of quality health insurance for low- and middle-income earners.

Notwithstanding government regulation, all businesses also have a responsibility to respect human rights and ensure that they do not cause or contribute to human rights abuses under the United Nations Guiding Principles on Business and Human Rights. Companies that have a role in setting drug prices, including pharmaceutical manufacturers, pharmacy benefit managers, health plan providers, and pharmacies, should take steps to identify and rectify practices that contribute to rendering insulin unaffordable for people who need it.

"Our system of unregulated and often unmitigated high drug prices is cruel and regressive, and has allowed companies to gouge some of the most vulnerable people in the country for a product they cannot live without," McConnell said. "But we have the tools to fix this crisis."

Older

MOTORISTS STILL PAYING DEARLY FOR INSURANCE

Newer

Let's Talk Interactive Achieves HIPAA Compliance With Compliancy Group

Advisor News

  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
  • Election results cloud retirement legislation outlook, experts say
  • Planning for the missing chapter
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
  • Jackson Launches Direct-to-Consumer Annuity Offering
More Annuity News

Health/Employee Benefits News

  • Reports Outline Managed Care Study Results from Harvard University (Inpatient-Only List Removals Shifted Procedures To The Outpatient Setting And Reduced Medicare Spending): Managed Care
  • Health and Humor: Picking a Medicare insurance plan is daunting
  • Obamacare is getting more expensive in Indiana
  • Hays City Commission to consider bids for health insurance, sports complex improvements
  • CHOICE arrangements: Not your father’s workplace health insurance
More Health/Employee Benefits News

Life Insurance News

  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • U-Haul Holding Company to Participate in Deutsche Bank Conference
  • NAIC task force to address LTC riders
  • Protective names Kurt Meyers Chief Legal Officer and Fernando Levy Chief Digital & AI Officer
  • Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.